Featured Article Main Category: Multiple Sclerosis Also Included In: Stem Cell Research Article Date: 18 Aug 2013 - 2:00 PDT

Current ratings for: Groundbreaking multiple sclerosis stem cell trial approved

4.7 (10 votes)

4.25 (4 votes)

The US Food and Drug Administration (FDA) has approved a new clinical trial of a groundbreaking strategy using stem cells for the treatment of MS (multiple sclerosis).

Researchers from the Tisch MS Research Center of New York say the FDA has granted approval to begin early clinical investigation (phase 1 trial) of autologous neural stem cells in the treatment of MS.

Multiple sclerosis is a chronic disease that attacks the central nervous system (the spinal cord, optic nerves and brain). Common symptoms are numbness of the limbs, but more severe cases can lead to paralysis and blindness.

According to the Multiple Sclerosis Foundation, there are currently between 350,000 to 500,000 people in the US who have been diagnosed with MS, and 200 people are diagnosed with the disease every week.

The new regenerative strategy will involve using autologous, mesenchymal stem cell-derived neural progenitor cells (MSC-NPs), which will be harvested from the bone marrow of 20 MS patients who meet the criteria for the trial.

The stem cells will then be injected into the cerebrospinal fluid that surrounds the spinal cords of the patients.

See the article here:
Groundbreaking multiple sclerosis stem cell trial approved